INTRODUCTION

Dermoscopy is a valuable noninvasive
technique that increases diagnostic accuracy in melanoma and non-melanoma skin cancer [1, 2] . Recently, its use as an aid in the monitoring of topical treatment response has also been described [2] [3] [4] [4, 5] .
This case report exemplifies the usefulness of dermoscopy in the assessment of residual disease after incomplete surgical excision and also in the monitoring of topical treatment response. (Fig. 4) . Six weeks after the incomplete surgical excision, the esthetic result was acceptable (Fig. 5) . However, dermoscopy confirmed the persistence of the tumor characterized by a large arborizing vessel (Fig. 6) . The patient and her family members denied a second surgical intervention and/or radiotherapy. For this reason and due to the ease of at-home application, daily topical treatment with 5% imiquimod cream for 8 weeks was started (Fig. 7) . Follow-up was performed every 3 weeks. Clinically and dermoscopically the patient revealed an appropriate response to the topical treatment characterized mainly by erythema and mild ulceration (Fig. 8) . Four weeks after the end of treatment, the clinical esthetic result was acceptable (Fig. 9) . At 12 months after the end of treatment dermoscopy confirmed the absence of any signs of recurrence (Fig. 10) . The patient was last seen 
CASE REPORT
DISCUSSION
Basal cell carcinoma is the most frequent cancer of the skin and its incidence is increasing worldwide [4] . Surgery, including Mohs micrographic surgery, is considered the ''gold standard'' of treatment and the most effective in terms of recurrence rates. Rates of incomplete excision of BCC range from 4% to 16.6% [6] . Incomplete excision has been associated with various recurrence rates ranging from 26% to 67% and 50% of recurrences occur within the next 6-12 months [6] . Certain anatomic locations such as the nose and inner canthus, as well as certain histologic subtypes such as infiltrative and multifocal, have been associated as predictive factors for incomplete excision [6] . In cases where the surgical intervention is unable to completely remove the tumor, adjuvant therapy such as a second surgical procedure, radiotherapy, photodynamic therapy and topical immunotherapy are used [7] . Imiquimod is a Toll-like receptor-7/8 (TLR-7/8) agonist that acts as a topical immune response modifier and has been reported as a non-surgical alternative for the treatment of BCC, particularly for the superficial subtype [7, 8] . Topical imiquimod 5% cream promotes a Th-1 immune response aimed at Fig. 9 Four weeks after the end of 5% imiquimod treatment the clinical esthetic result was acceptable Fig. 10 One year later the patient had no signs of recurrence confirmed by dermoscopy However, severe side effects, limited response rates, and rapid development of drug resistance may limit the therapeutic success of SMO
antagonists. This reflects the need for the identification of alternative and additional strategies repressing oncogenic HH signaling [9] . Imiquimod 5% may be one of such alternatives as a topical, safe and relatively easy to use drug for the treatment of different BCC subtypes as adjuvant or neoadjuvant therapy [10] .
CONCLUSION
Our case report exemplifies that dermoscopy is a valuable diagnostic aid that also serves to assess tumor recurrence/residual disease and to monitor topical treatment response. It also adds further evidence to the use of imiquimod as an important topical neoadjuvant or adjuvant therapy for the treatment of BCC and residual disease in cases with incomplete surgical excision [10, 11] .
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